EU Pharma Strategy To Balance Innovation Incentives & Competition
Stakeholders Have Different Views On ‘Unmet Medical Need’
Delegates at this week’s TOPRA conference heard the European Commission’s “holistic” vision of what it would like to achieve through its pharmaceutical strategy, including incentives for innovation, security of the supply chain, product shortages, real world evidence and big data, and the availability and affordability of medicines.
You may also be interested in...
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.
The EU has ambitious plans for dealing with future health crises, bolstering needs-led innovation, improving access to medicines, and tackling drug shortages.
The European medicines network needs to quickly build up its capabilities in the area of data analysis and digital transformation, but finding the necessary staff is difficult in the face of stiff competition from both the pharmaceutical industry and the likes of Google and Facebook, according to the head of the Danish regulator.